Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. The transaction is worth up to a total of $415 million, including an undisclosed upfront payment, potential discovery, development, and commercialisation… Read More
Eli Lilly and Alchemab Therapeutics hope to discover novel therapeutic candidates to treat amyotrophic lateral sclerosis (ALS) as part of a new research collaboration. Alchemab’s technology platform uses patient samples from individuals with unusually slow rates of disease progression to identify antibodies associated with resilience. … Read More
Alchemab Therapeutics has been awarded a grant of $595,000 by The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease (PD) programme. The grant will fund research performed at Alchemab following its identification of antibodies that target prostaglandin biology in PD, a potentially unique… Read More
Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate. The data was announced at the Antibody Industrial Symposium in Tours, France, June 22-23, 2023. ATLX-1088 is a potential… Read More
